IFNB1 and AL amyloidosis: As for the Phase I clinical trial (NCT03017820) of intravenous administration of VSV-IFNβ-NIS for patients with relapsed refractory multiple myeloma, acute myeloid leukemia and T-cell lymphoma the published preliminary report showed that VSV-IFNβ-NIS is well tolerated at dose level 1.7 × 1011 TCID50.